Impact of silymarin‐supplemented cookies on liver enzyme and inflammatory markers in non‐alcoholic fatty liver disease patients
Food Science & Nutrition · 2024-10 · 12 (10) · 7273-7286
DOI: 10.1002/fsn3.4348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Food Science & Nutrition, online erschienen am 17.07.2024. Verfasst von Hafiza Madiha Jaffar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Allied Health Sciences University Institute of Diet & Nutritional Sciences, University of Lahore Lahore Pakistan. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nonalcoholic fatty liver disease (NAFLD) is a growing public health concern characterized by fat accumulation and severe disorders like nonalcoholic steatohepatitis (NASH), which are influenced by obesity, inflammatory processes, and metabolic pathways. This research investigates the potential of silymarin‐supplemented cookies in managing NAFLD by evaluating their impact on liver enzyme activity, inflammatory markers, and lipid profiles. A clinical trial in Lahore, Pakistan, involved 64 NAFLD patients. Participants were divided into placebo and three treatment groups, with the latter receiving silymarin‐supplemented cookies for 3 months. The study assessed liver enzyme levels and inflammatory markers, at baseline and after the intervention, utilizing statistical analyses to evaluate differences. The lipid profile and renal function test (RFT) were also measured at baseline and after 3 months in each group for safety assessment. After 3 months, the treatment groups indicated more significant decreases in liver enzymes compared to the placebo group ( p ≤ .05). Treatment 3 showed significant reductions in alanine aminotransferase (ALT) (64.39–49.38 U/L) and aspartate aminotransferase (AST) (61.53–45.38 U/L). Treatment 3 also showed improvements in alkaline phosphatase (ALP) levels and the AST/ALT ratio. Additionally, the treatment group demonstrated a significant reduction in inflammatory markers. Treatment 3 showed a significant decrease in C‐reactive protein (CRP) (6.32–3.39 mg/L) and erythrocyte sedimentation rate (ESR) (38.72–23.86 mm/h), indicating that individuals with NAFLD may benefit from the intervention's potential benefits in lowering inflammation. The study revealed that an intervention significantly improved the inflammatory markers, liver enzymes, and lipid profiles of NAFLD participants, suggesting potential benefits for liver health.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Allied Health Sciences University Institute of Diet & Nutritional Sciences, University of Lahore Lahore Pakistan.
- School of Food and Biological Engineering Jiangsu University Zhenjiang China.
- Allied Health Sciences The University of Lahore Lahore Pakistan.
- Department of Biomedical Sciences Jimma University Jimma Ethiopia.
- Present address: Division of Research & Development Lovely Professional University Phagwara Punjab 144001 India.
ORCID-Profile: Tabussam Tufail, Tabarak Malik
Zitieren
APA
Jaffar, H. M., Bader Ul Ain, H., Tufail, T., Hanif, A., & Malik, T. (2024). Impact of silymarin‐supplemented cookies on liver enzyme and inflammatory markers in non‐alcoholic fatty liver disease patients. Food Science & Nutrition, 12(10), 7273-7286. https://doi.org/10.1002/fsn3.4348
Vancouver
Jaffar HM, Bader Ul Ain H, Tufail T, Hanif A, Malik T. Impact of silymarin‐supplemented cookies on liver enzyme and inflammatory markers in non‐alcoholic fatty liver disease patients. Food Science & Nutrition. 2024;12(10):7273-7286. doi:10.1002/fsn3.4348
BibTeX
@article{Jaffar2024,
author = {Jaffar, Hafiza Madiha and Bader Ul Ain, Huma and Tufail, Tabussam and Hanif, Asif and Malik, Tabarak},
title = {Impact of silymarin‐supplemented cookies on liver enzyme and inflammatory markers in non‐alcoholic fatty liver disease patients},
journal = {Food Science & Nutrition},
year = {2024},
volume = {12},
number = {10},
pages = {7273--7286},
doi = {10.1002/fsn3.4348}
}
EUVIMED